ImmunityBio Reports Sevenfold Revenue Surge Fueled by Cancer Drug Success

ImmunityBio reports 700% revenue growth for ANKTIVA, supported by 84% bladder preservation data and expansion into 33 global markets with strong financial backing.

ImmunityBio, Inc. has revealed a dramatic acceleration in commercial performance for its flagship immunotherapy, ANKTIVA. Speaking at the Citizens Life Sciences Conference in Miami Beach this week, CEO Richard Adcock presented figures showing the treatment's revenue soared by 700% year-over-year. The volume of units sold saw an even more pronounced increase, climbing 750%.

Robust Clinical Data and Global Market Access

The commercial momentum is supported by compelling long-term efficacy data. Results from the QUILT-3.032 study in non-muscle invasive bladder cancer patients demonstrate a bladder preservation rate of 84% at 36 months, coupled with a complete response rate of 71%. Researchers have been able to track this durable efficacy for a period extending to 53 months.

Concurrently, the company's global footprint is expanding. It now holds marketing authorizations in 33 countries. A recent accelerated approval from the Saudi Food and Drug Authority for ANKTIVA in specific forms of metastatic non-small cell lung cancer marks a strategic entry into the Middle East, building upon existing commercial infrastructure in the United States and Europe.

Regulatory Pathway and Financial Foundation

Significant regulatory milestones are shaping the company's near-term trajectory. ImmunityBio has resubmitted a supplemental Biologics License Application (sBLA) to the U.S. FDA for the treatment of papillary bladder carcinoma, following prior discussions with the agency. In a key development for clinical practice, the National Comprehensive Cancer Network (NCCN) updated its bladder cancer guidelines on March 17, incorporating the ANKTIVA and BCG combination as a Category 2A recommendation for BCG-unresponsive patients. While formal FDA labeling for this indication is pending, the guideline inclusion provides a clinical framework for physicians.

Looking ahead, the company is preparing for additional sBLA and BLA submissions through the end of 2026. These filings will be supported by completed enrollment of 366 patients in a BCG-naïve study. ImmunityBio states it is well-positioned for this regulatory schedule, citing a strong liquidity position of approximately $250 million.

The financial base for this planned growth was underscored by 2025 net product revenue, which reached $113 million. This figure establishes the foundation for the company's anticipated progress in the coming year.